Similar articles

• Isochromosome for derivative 17q in acute promyelocytic leukemia: evidence for two copies of PML-RARA and favorable response to all-trans-retinoic acid therapy.

  Park JP, Fairweather RB, Mohandas TK. Park JP, et al. Genes Chromosomes Cancer. 1997 Feb;18(2):151-3. Genes Chromosomes Cancer. 1997. PMID: 9115966 No abstract available.
• APL, a model disease for cancer therapies?

  de Thé H, Chelbi-Alix MK. de Thé H, et al. Oncogene. 2001 Oct 29;20(49):7136-9. doi: 10.1038/sj.onc.1204851. Oncogene. 2001. PMID: 11704841 Review. No abstract available.
• Differentiation therapy of acute promyelocytic leukemia: clinical and molecular features.

  Miller WH Jr. Miller WH Jr. Cancer Invest. 1996;14(2):142-50. doi: 10.3109/07357909609018889. Cancer Invest. 1996. PMID: 8597899 Review. No abstract available.
• PML/RAR alpha + ATRA = CR. A comment on acute promyelocytic leukaemia: molecular pathology and treatment.

  Dyer MJ. Dyer MJ. Eur J Cancer. 1994;30A(5):573-4. doi: 10.1016/0959-8049(94)90518-5. Eur J Cancer. 1994. PMID: 8080665 No abstract available.
• [M3, promyelocytic leukemia].

  Tsuruoka N. Tsuruoka N. Ryoikibetsu Shokogun Shirizu. 1998;(22 Pt 3):65-7. Ryoikibetsu Shokogun Shirizu. 1998. PMID: 9851086 Review. Japanese. No abstract available.